Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C20H33N2O.CH3O4S |
| Molecular Weight | 428.586 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COS([O-])(=O)=O.C[N+]1(C)CCN(CC(O)(C2CCCCC2)C3=CC=CC=C3)CC1
InChI
InChIKey=NSILVESQCSUIAJ-UHFFFAOYSA-M
InChI=1S/C20H33N2O.CH4O4S/c1-22(2)15-13-21(14-16-22)17-20(23,18-9-5-3-6-10-18)19-11-7-4-8-12-19;1-5-6(2,3)4/h3,5-6,9-10,19,23H,4,7-8,11-17H2,1-2H3;1H3,(H,2,3,4)/q+1;/p-1
| Molecular Formula | CH3O4S |
| Molecular Weight | 111.097 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C20H33N2O |
| Molecular Weight | 317.4888 |
| Charge | 1 |
| Count |
|
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Hexocyclium is an old anticholinergic drug. Hexocyclium is an antimuscarinic. Hexocyclium in therapeutic doses produces a prolonged reduction of gastric acidity. It was used for the treatment of peptic ulcer. Hexocyclium is effective for the control of cramps and diarrhea in cases of irritable bowel syndrome.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 13.0 nM [IC50] | |||
Target ID: CHEMBL211 |
40.0 nM [IC50] | ||
| 9.0 nM [IC50] | |||
| 39.0 nM [IC50] | |||
Target ID: CHEMBL2035 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2704370 |
14.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Tral Approved UseTral is used in the treatment of peptic ulcers. Launch Date1959 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13520691
Single oral doses of 25 mg and 50 mg
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9183081
Acetylcholine-induced concentration-dependent tonic contraction of isolated rat fundus was concentration-dependently antagonized by hexocyclium (KB = 2.82 x 10(-10)M).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 07:30:11 GMT 2025
by
admin
on
Wed Apr 02 07:30:11 GMT 2025
|
| Record UNII |
84OPZ2Q0VB
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Wed Apr 02 07:30:11 GMT 2025 , Edited by admin on Wed Apr 02 07:30:11 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
101587
Created by
admin on Wed Apr 02 07:30:11 GMT 2025 , Edited by admin on Wed Apr 02 07:30:11 GMT 2025
|
PRIMARY | |||
|
30256
Created by
admin on Wed Apr 02 07:30:11 GMT 2025 , Edited by admin on Wed Apr 02 07:30:11 GMT 2025
|
PRIMARY | |||
|
SUB08040MIG
Created by
admin on Wed Apr 02 07:30:11 GMT 2025 , Edited by admin on Wed Apr 02 07:30:11 GMT 2025
|
PRIMARY | |||
|
204-097-2
Created by
admin on Wed Apr 02 07:30:11 GMT 2025 , Edited by admin on Wed Apr 02 07:30:11 GMT 2025
|
PRIMARY | |||
|
115-63-9
Created by
admin on Wed Apr 02 07:30:11 GMT 2025 , Edited by admin on Wed Apr 02 07:30:11 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201325
Created by
admin on Wed Apr 02 07:30:11 GMT 2025 , Edited by admin on Wed Apr 02 07:30:11 GMT 2025
|
PRIMARY | |||
|
DTXSID4023123
Created by
admin on Wed Apr 02 07:30:11 GMT 2025 , Edited by admin on Wed Apr 02 07:30:11 GMT 2025
|
PRIMARY | |||
|
100000083980
Created by
admin on Wed Apr 02 07:30:11 GMT 2025 , Edited by admin on Wed Apr 02 07:30:11 GMT 2025
|
PRIMARY | |||
|
C015922
Created by
admin on Wed Apr 02 07:30:11 GMT 2025 , Edited by admin on Wed Apr 02 07:30:11 GMT 2025
|
PRIMARY | |||
|
m6012
Created by
admin on Wed Apr 02 07:30:11 GMT 2025 , Edited by admin on Wed Apr 02 07:30:11 GMT 2025
|
PRIMARY | Merck Index | ||
|
DBSALT001391
Created by
admin on Wed Apr 02 07:30:11 GMT 2025 , Edited by admin on Wed Apr 02 07:30:11 GMT 2025
|
PRIMARY | |||
|
235430
Created by
admin on Wed Apr 02 07:30:11 GMT 2025 , Edited by admin on Wed Apr 02 07:30:11 GMT 2025
|
PRIMARY | RxNorm | ||
|
672
Created by
admin on Wed Apr 02 07:30:11 GMT 2025 , Edited by admin on Wed Apr 02 07:30:11 GMT 2025
|
PRIMARY | |||
|
84OPZ2Q0VB
Created by
admin on Wed Apr 02 07:30:11 GMT 2025 , Edited by admin on Wed Apr 02 07:30:11 GMT 2025
|
PRIMARY | |||
|
C65851
Created by
admin on Wed Apr 02 07:30:11 GMT 2025 , Edited by admin on Wed Apr 02 07:30:11 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
PARENT -> SALT/SOLVATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |